Table 1 Grouped Characteristics of Included Studies and Cases.
From: Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates
Studies/Cases | n (%) |
|---|---|
Gestational age of the NB (weeks), median, Q1-Q3, (n = 36) | 36.5 (36; 38) |
Full-term NB (n = 39), yes | 21 (53.85) |
Sex of the NB (n = 44), male | 31 (70.45) |
Weight (g), median, Q1-Q3, (n = 40) | 2927 (2150; 3240) |
Rhabdomyoma (n = 48) | |
Multiple | 35 (72.92) |
Single | 23 (27.08) |
Location of the rhabdomyoma (n = 47) | |
LVOT | 17 (36.17) |
RV | 13 (27.66) |
LV | 10 (21.28) |
RVOT | 4 (8.51) |
RV/LV | 2 (4.26) |
RA | 1 (2.13) |
Reason for initiating treatment (n = 48) | |
Hemodynamic | 43 (89.58) |
Hemodynamic/Arrhythmia | 3 (6.25) |
Arrhythmia | 2 (4.17) |
